cMyc/miR-125b-5p signalling determines sensitivity to bortezomib in preclinical model of cutaneous T-cell lymphomas.
Successful/effective cancer therapy in low grade lymphoma is often hampered by cell resistance to anti-neoplastic agents. The crucial mechanisms responsible for this phenomenon are poorly understood. Overcoming resistance of tumor cells to anticancer agents, such as proteasome inhibitors, could impr...
Main Authors: | Valentina Manfè, Edyta Biskup, Ayalah Willumsgaard, Anne Guldhammer Skov, Dario Palmieri, Pierluigi Gasparini, Alessandro Laganá, Anders Woetmann, Niels Ødum, Carlo Maria Croce, Robert Gniadecki |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2013-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC3602111?pdf=render |
Similar Items
-
A proteomic study of cMyc improvement of CHO culture
by: Dunn Michael J, et al.
Published: (2010-03-01) -
Temporal Requirements of cMyc Protein for Reprogramming Mouse Fibroblasts
by: Corey Heffernan, et al.
Published: (2012-01-01) -
miR-122 regulates p53/Akt signalling and the chemotherapy-induced apoptosis in cutaneous T-cell lymphoma.
by: Valentina Manfè, et al.
Published: (2012-01-01) -
Growth dynamics and cyclin expression in cutaneous T-cell lymphoma cell lines
by: Edyta Biskup, et al.
Published: (2010-05-01) -
cMYC expression in thyroid follicular cell-derived carcinomas: a role in thyroid tumorigenesis
by: Hany I. Sakr, et al.
Published: (2017-10-01)